Product Name:
PFTAIRE1-ANT
Product Number:
ab-nk287-1
Target Full Name: Serine/threonine protein kinase PFTAIRE-1
Target Alias: CDK14; KIAA0834; PFT1; PFTAIRE protein kinase 1; PFTK1; Serine/threonine protein kinase PFTAIRE-1
Product Type Specific: CDK14 (PFTAIRE) protein kinase pan-specific antibody
Antibody Code: NK287-1
Antibody Target Type: Pan-specific
Protein UniProt: O94921
Protein SigNET: PFTAIRE1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human PFTAIRE1 (CDK14) sequence peptide Cat. No.: PE-01BEN70
Antibody Immunogen Sequence: CAEKIGKMKKLRRTLSESFS
Antibody Immunogen Description: Corresponds to amino acid residues A10 to S28; Post-N-terminus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very weak immunoreactivity of a target-sized protein by Western blotting in mouse skeletal muscle and testes.
Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Dog | Mouse | Chicken.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 47-55 kDa.
Antibody Specificity: High-very high
Antibody Cross Reactivity: No significant cross-reactivities detected in various human cancer cell lines, including A431, HEK-293, HeLa, HepG2, Jurkat and MCF7 cells, except for weak signals with ~140 and ~68 kDa proteins in Jurkat cells. No cross-reactivities were detected in mouse brain, skeletal muscle, testes and thymus, except for a 65 kDa protein in mouse testes.
Related Product 1: PFTAIRE1 (10-28) antibody blocking peptide (Cat. No.: PE-01BEN70)
Related Product 2: PFTAIRE2 expression antibody (Cat. No.: AB-NK004-2)
Related Product 3: PFTAIRE2 expression antibody (Cat. No.: AB-NK004-3)
Related Product 4: PFTAIRE2 Y114 phosphorylation antibody (Cat. No.: AB-PK957)
Scientific Background: CDK14 (PFTAIRE1; PFTK1) is a 58 kDa protein-serine/threonine kinase of the CMGC group and CDK family. It is expressed primarily in the postnatal and adult nervous system, and regulates cell cycle progression, specifically the G2/M transition, and activates the Wnt/b-catenin signalling pathway by phosphorylating LRP6 at Ser-1490. Its phosphotransferase activity is stimulated by association with cyclins CCDN3 and CCNY. It binds to 14-3-3 isoforms when it is phosphorylated at Ser-119, which can be enhanced by CCNY. It is repressed by CDKN1A. It is expressed at high levels in brain, pancreas, kidney, heart, testis, and ovary. It is located in the cytosol, nucleoplasm, and plasma membrane, often recruited to the membrane by CCNY. It is implicated in Parkinson's disease (PD), and reducing CDK14 levels has been shown to reduce toxic a-synuclein aggregation. Overexpression of CDK14 is associated with tumor progression in various cancers, including osteosarcoma, glioblastoma, and pancreatic cancer, often by driving proliferation. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis. Positive expression of CDK14 when compared to its negative expression predicts resistance to chemotherapy and poorer prognosis in patients with oesophageal squamous cell carcinomas over a 5-year period. This description may include information annotated by UniProt and/or Google AI.